SCHEMBL13544358

SCHEMBL13544358

O=C(NCC1CCN(c2cccc(F)c2O)CC1)[C@H](O)[C@@H](O)C(=O)N1CCCC1

nearest known ligand 0.49

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
▸ ADAM17 P78536 9/20 0.49
▸ ALDH1A1 P00352 1/20 0.39
▸ ADAM10 O14672 1/20 0.39
▸ MMP12 P39900 1/20 0.39
▸ MMP13 P45452 1/20 0.39
▸ KMT2A Q03164 1/20 0.37
▸ NPC1 O15118 1/20 0.36
▸ LMNA P02545 1/20 0.36
▸ ALOX15 P16050 1/20 0.36
▸ TSHR P16473 1/20 0.36
▸ MAPK1 P28482 1/20 0.36
▸ CHRM4 P08173 2/20 0.36
▸ GAA P10253 2/20 0.35
▸ POLB P06746 1/20 0.35
▸ NPSR1 Q6W5P4 1/20 0.35
▸ KCNQ2 O43526 1/20 0.35
▸ ADORA2A P29274 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8224861 0.86 ADAM17 (0.44) ADAM17ALDH1A1ADAM10MMP12MMP13
SCHEMBL8222013 0.85 ADAM17 (0.44) ADAM17ALDH1A1ADAM10MMP12MMP13
SCHEMBL8275877 0.84 ADAM17 (0.49) ADAM17ALDH1A1KMT2ANPC1LMNA
SCHEMBL8274406 0.82 ADAM17 (0.49) ADAM17ADAM10MMP12MMP13KMT2A
SCHEMBL8221362 0.81 ADAM17 (0.66) ADAM17ALDH1A1ADAM10MMP12MMP13
SCHEMBL8222801 0.80 CHRM4 (0.49) ADAM17ADAM10MMP12MMP13CHRM4
SCHEMBL8273310 0.79 GAA (0.44) ADAM17ALDH1A1KMT2ANPC1GAA
SCHEMBL8274451 0.79 ADAM17 (0.45) ADAM17ALDH1A1ADAM10MMP12MMP13
SCHEMBL8273592 0.78 HTT (0.46) ADAM17ALDH1A1KMT2ANPC1GAA
SCHEMBL8273348 0.78 ADAM17 (0.53) ADAM17CHRM4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7652020-B2 novel hydantoin derivatives to inhibit matrix metalloproteinases (MMPs), a disintegrin and metalloproteases (ADAMs) and/or tumor necrosis factor alpha converting enzyme (TACE) and in so doing prevent the release of tumor necrosis factor alpha (TNF- alpha ); autoimmune diseases; side effect reduction SCHERING CORPORATION (US) 2010-01-26 — — US disclosed
Send feedback